Shangai Fosun to buy 86% stake in Gland Pharma for $1.26bn
As per the agreement, the Chinese firm will buy all of the Gland Pharma shares owned by KKR Floorline Investments apart from the shares purchased from the company's other shareholders.
Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.
Espada is a wholly-owned subsidiary of Mission Pharmacal Company (Mission) and adds breadth to Mission’s established line of dermatological drug products. Prior to this acquisition, Mission offered prescription